Key Takeaways
- Revenue crosses ₹500 Cr, margin expands: Q1 revenue exceeded ₹500 Crores and gross margin rose 95 bps to 51.5%, driven by product mix and raw material cost relief.
- Teva plant is a deliberate drag: The acquired Goa facility is operational but revenue is negligible; management calls it "pain before gain" and does not expect break-even until Q1 FY25.
- US pricing stabilizes, growth ambition set: Price erosion has tapered and management expects to double US revenue in the next couple of years, though US margins currently sit below the company average.
- UK delivers standout growth: The UK and new formulation markets grew 24.8% YoY on new launches, share gains, and currency tailwinds, with 3–4 product launches planned each quarter.
- What to watch next quarter: Whether the Teva plant stays on budget as expenses rise with capacity, the US FDA EIR report on the Goa facility, and progress toward the ₹2,000 Cr full-year revenue run rate.
Teva Acquisition: The Drag and the Payoff
- Current state is deliberate investment: The plant is operational but supplying only a few items under the Teva contract, so revenue is very small while employee and other overhead costs have already been onboarded.
- Cost base will rise before it leverages: Q1 saw ₹11 crores in higher expenses from the facility, which management calls the base level; costs will increase further as capacity and manpower scale up toward full production.
- Break-even pushed to next financial year: Management explicitly declined to confirm break-even this year, stating full optimization and break-even will come from Q1 of next financial year, with the last quarter of this year being the best quarter for Teva.
- Revenue ramp is back-end loaded: Sales from the plant are negligible now; management expects ₹40–₹45 crores by the end of this year, with additional revenue from capacity enhancement trickling in during the last quarter of FY24, and substantial revenue only in FY2025.
- Manufacturing platform, not a new go-to-market: Teva will be used as a manufacturing platform while distribution and marketing leverage the existing infrastructure, so operating leverage comes purely from higher production output on the capex already invested.
- Capacity addresses three-year horizon: The plant is expected to address the company's requirements for at least the next three years.
Mark Saldanha: "So obviously like I mentioned in my previous concalls, there will be some pain before any gain..."
US Market: Stabilization and Ambition
- Pricing pressure has eased: Price erosion has tapered down compared to the historic levels of last year; management sees stability in the market and notes pricing pressure is not as bad as it was.
- Growth ambition is explicit: Management expects to double revenue in the US in the next couple of years, citing the large market size and the company's currently small base as giving ample room for growth.
- Margins are sub-par today: US geographical margins are currently lower than the company average because operational leverage has yet to kick in; as revenue generation grows, better bottom-line expansion is expected over time.
- Product launch pipeline building: The company plans 3–4 launches in the US in FY2024, including the Advil dual action equivalent for which it became the first Indian company to receive US FDA approval.
- Regulatory process in motion: The US FDA observations on the Goa facility are being answered this week; management sees it as a normal process of questions and SOP updates with no issues foreseen, and expects the EIR report in a couple of months.
Mark Saldanha: "Well market size in US is huge and we expect to double our revenue in the next couple of years, but we are relatively very small in the US market. So that gives us the potential for growth."
UK and Formulation Markets: The Growth Engine
- UK delivered 24.8% YoY growth: The UK and new formulation markets grew on the back of new product launches, incremental market share gains with existing customers, and better realization from currency fluctuation.
- Growth is repeatable and cadenced: The UK growth formula rests on product mix improvement, gaining new market share from present clients, and launching 3–4 products every quarter, making the trajectory systematic rather than lumpy.
- OTC strategy is segment-focused: The immediate priority is to create a complete product offering in three key OTC therapeutic segments: pain, cough and cold, and digestives.
- OTC is structurally more stable than RX: Management contrasted the two markets: prescription sees high volatility with prices tanking overnight, while OTC is relatively more stable because it operates on contracts, though prices will eventually correct at contract renewal.
Margins: Current Strength, Full-Year Caution
- Q1 gross margin expanded 95 bps to 51.5%: The improvement came from a better product mix and a reduction in rates of a few raw materials; management expects gross margins to remain at this level throughout the year.
- Q1 EBITDA margin touched 20.4%: This is up from approximately 18% last year, but management guided that full-year EBITDA margins will be range-bound at 17–19% due to variabilities including Teva acquisition costs.
- Medium-term margin target set: As Teva capacity utilization increases, EBITDA margin is expected to improve to 21–22%, with backward integration and cost management initiatives expanding margins in the coming years.
- Employee and other expenses rose on Teva: Employee expenses increased due to onboarding the acquired facility's workforce; other expenses rose on account of the newly acquired facility's operating costs.
- API prices have cratered to pre-COVID lows: After the COVID-era boom in API prices, prices have dropped heavily to prehistoric lows; management expects stability for at least the next 12 months.
Backward Integration and Capacity
- First DMF filing on track for September: The company expects to file at least two DMFs by this financial year, with a possible third by early next year, marking the start of its backward integration journey.
- Existing capacity has headroom: Excluding the Teva facility, current capacity utilization is around 70%, leaving room for organic growth without incremental capex.
- Working capital steady at ~120 days: The cycle has already come down a bit; as the Teva plant operates at full scale, incremental material and receivables will increase in line with sales, keeping the ratio range-bound.
- UK tax rate reset to 25%: The UK tax rate has moved up from 19% to 25%; management believes this will be the normal run rate going forward.
M&A and Capital Allocation
- European bolt-on dialogue is early-stage: Management is in dialogue with two target companies for asset-light bolt-on acquisitions in Europe, but described the discussions as far from any pen coming to paper and cautioned that 90% of M&A discussions do not close.
- Teva capex absorbed within growth plans: When asked for a ballpark FY2025 capex figure, management declined to give a number, stating only that it falls within overall growth plans.
Mark Saldanha: "We are in dialogue Viraj with actually two target companies, but nothing concrete to highlight, we are far away from any pen coming to paper per se, so I think it is too early to discuss anything relevant because these M&As and 90% of the time the probability factors are they do not go through."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue | Cross ₹2,000 Crores in FY2024 | FY2024 (extrapolated from Q1 run rate) |
| Full-year EBITDA margin | Range-bound at 17–19% | FY2024 |
| Gross margin | Remain at current level (~51.5%) | Throughout FY2024 |
| Teva plant revenue | ₹40–₹45 crores | By end of FY2024 |
| Teva plant break-even | Full optimization and break-even | Q1 FY25 |
| Teva substantial revenue | Meaningful contribution | FY2025 |
| US revenue | Double from current level | Next couple of years |
| US product launches | 3–4 launches including Advil dual action equivalent | FY2024 |
| Backward integration: first DMF | File first DMF | September 2024 |
| Backward integration: DMF count | At least two DMFs filed | FY2024 |
| US FDA Goa EIR report | Report received after answering observations | Couple of months from Q1-end |
| API pricing environment | Stability expected | At least next 12 months |
| EBITDA margin medium-term | Improve to 21–22% as Teva capacity utilization rises | As Teva ramps (no date) |
| Revenue growth trajectory | At least 15% revenue growth | Next two to three years |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Operating revenue | ₹500 cr, +15.3% YoY |
| US and North America revenue | ₹193.3 cr, +11.2% YoY |
| UK and new formulation markets revenue | ₹225.9 cr, +24.8% YoY |
| Australia and New Zealand revenue | ₹58.6 cr, +11.4% YoY |
| Rest of the world revenue | ₹22.2 cr |
| Gross margin | 51.5%, +95 bps YoY |
| EBITDA | ₹102 cr, +39.9% YoY and -6.9% QoQ |
| EBITDA margin | 20.4% |
| Profit after tax | ₹70.4 cr, +17% YoY |
| EPS | ₹1.52 |
| Cash from operations | ₹34.3 cr |
| Free cash flow | -₹47.2 cr, on account of high capex in the quarter |
| Capex incurred | ₹81.5 cr |
| R&D spend | ₹8.46 cr, 1.7% of sales |
| Total cash balance | ₹636 cr as of 30th June 2023 |
| Capacity utilization (excl. Teva) | ~70% |
| Teva facility cost loading in P&L | ~₹11 cr in the quarter |
| FY24 revenue guidance | Cross ₹2,000 cr |
| FY24 EBITDA margin guidance | 17–19% |
| Expected Teva revenue contribution in FY24 | ₹40–50 cr |
| UK tax rate | 25%, increased from 19% |
| Working capital cycle | ~120 days |